VEGFR-2-IN-66
VEGFR-2-IN-66 (Compound 6) is an orally active VEGFR-2 inhibitor with an IC50 value of 0.509 µM and an IC50 value of 7.48 μM for inhibiting the proliferation of MCF-7 cells. VEGFR-2-IN-66 exerts its anti-cancer activity by arresting the cell cycle, inducing apoptosis, and regulating gene expression, and can be used in the research of the breast cancer field[1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; VEGFR
Related Pathways
Apoptosis; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
O=C(NC1CCC(NC1=O)=O)CN(CC2)CCN2C3=NC4=CC=CC=C4C5=NN=CN35
Molecular Formula
C20H22N8O3
Molecular Weight
422.44
References & Citations
[1]Mabrouk RR, et al. Novel triazoloquinazoline derivatives as VEGFR inhibitors: synthesis, cytotoxic evaluation and in silico studies. Future Med Chem. 2025 Mar;17 (5) :529-541.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
VEGFR2/KDR/Flk-1
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNUB2180-500 1x 500 µL
EGFR (Epidermal Growth Factor Receptor) (F4), 0.2mg/mL
Sign In for Pricing
View Details 
BNC470227-500 1x 500 µL
Milk Fat Globulin (MFG-06), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 